Quality and Analytical Testing
How Is Peptide Purity Tested?
Quick answer
Peptide purity is tested by reversed-phase HPLC, which reports the target peak as a percentage of total integrated peak area, and by mass spectrometry, which confirms that the main species has the expected mass. Purity is not peptide content: content also requires water, counter-ion and assay data. A complete claim combines HPLC area percent, identity, water by Karl Fischer and an assay such as amino acid analysis.
Key facts at a glance
| Purity | HPLC area percent, typically 95% or 98%+ release specifications |
|---|---|
| Identity | ESI-MS or MALDI-TOF, reported with ppm error against the sequence |
| Content | Mass fraction of peptide, corrected for water, counter-ion and salts |
| Water | Karl Fischer titration, usually 2–10% w/w for lyophilised powder |
| Assay options | Amino acid analysis, nitrogen determination, or quantitative HPLC against a standard |
| Mass balance | Peptide + water + counter-ion + residual solvent + inorganics should approach 100% |
Four different measurements hide behind the word purity
Suppliers and buyers often use "purity" for four different quantities. Keeping them separate prevents most of the arguments that follow a delivery.
| Measurement | Question it answers | Typical method |
|---|---|---|
| HPLC area percent | What share of the UV-absorbing material is the target peptide? | Reversed-phase HPLC at 214 nm |
| Identity | Is the main species the sequence we ordered? | ESI-MS or MALDI-TOF |
| Peptide content | How many milligrams of peptide are in this vial? | Amino acid analysis or nitrogen assay, with water and counter-ion data |
| Mass balance | Do the measured components add up to the weighed mass? | Summation of content, water, counter-ion, solvent and ash |
A supplier who reports only the first row has told you about relative purity and nothing about quantity. For a cell assay or an animal study, the difference between 10 mg of vial content and 8.4 mg of peptide is the difference between the intended dose and a 16% underdose.
HPLC area percent: relative, not absolute
The calculation is the target peak area divided by the sum of all integrated peak areas. Everything that determines which peaks are integrated therefore determines the result: the gradient length, the column, the wavelength, the integration threshold and the baseline handling. A 98% result obtained with a 0.5% threshold on a 12-minute gradient is not comparable with a 95% result obtained with a 0.05% threshold on a 45-minute gradient.
Area percent also assumes that all species have the same UV response per unit mass, which is not true. Response at 214 nm depends on the number of peptide bonds and their environment, so a truncation product is not necessarily represented in proportion to its mass. Area percent is best treated as a reproducible relative measure under a fixed method, which is exactly what a release specification needs, and not as a statement about milligrams.
Assay by amino acid analysis or nitrogen determination
Amino acid analysis hydrolyses the peptide into free residues, separates them, and quantifies each one. Because the sequence predicts the molar ratio of every residue, the measured composition both confirms identity and gives the molar amount of peptide in the weighed sample. It is the most direct way to establish peptide content, and it catches errors that HPLC cannot, such as a peptide with the right mass but the wrong residue ratio.
The method has known limitations. Tryptophan is destroyed by standard acid hydrolysis unless a separate procedure is used; cysteine needs oxidation or alkylation before hydrolysis; and hydrophobic or sterically hindered bonds may hydrolyse incompletely. Nitrogen determination by Kjeldahl or Dumas is a complementary approach: it measures total nitrogen, which is not affected by water or by a nitrogen-free counter-ion such as trifluoroacetate, and converts to peptide content using a sequence-specific factor. Because the two methods are sensitive to different errors, agreement between them is stronger evidence than either alone.
Peptide content: correcting for water, TFA and salt
Peptide content is the mass fraction of the vial that is actually peptide. It is always lower than HPLC purity, sometimes by a wide margin. A worked example makes the arithmetic concrete.
| Component | % w/w | Mass in a 10 mg vial |
|---|---|---|
| Peptide (by amino acid analysis) | 84.0 | 8.40 mg |
| Water (Karl Fischer) | 6.0 | 0.60 mg |
| Trifluoroacetate counter-ion | 7.5 | 0.75 mg |
| Residual acetonitrile and other solvents | 1.0 | 0.10 mg |
| Inorganic salts and ash | 1.5 | 0.15 mg |
| Total | 100.0 | 10.00 mg |
This batch may well be 97% pure by HPLC and still contain 84% peptide. Neither figure is wrong; they answer different questions. When a protocol calls for a molar amount, calculate from peptide content, not from vial weight. When a specification calls for purity, use the HPLC figure and cite the method. Confusing the two is the single most common source of unexplained assay variability in labs that work with synthetic peptides.
Mass balance: where the rest of the batch went
Mass balance is the accounting check. If peptide content is 84%, water 6%, counter-ion 7.5%, solvent 1% and ash 1.5%, the components close to 100% and nothing major is unmeasured. If they sum to 88%, roughly 12% of the mass is unidentified, and the likely candidates are an unmeasured counter-ion, a higher water content than the sample taken for Karl Fischer, or simply a weighing error.
Mass balance is not usually a release specification, but it is the quickest way to see whether the analytical package is complete. A COA that reports peptide content of 99% by amino acid analysis with no water or counter-ion data is internally inconsistent for a lyophilised TFA salt, because the mass has to go somewhere. Reviewers should treat such a document as incomplete rather than excellent.
System suitability and method validation
A purity figure inherits the quality of the method that produced it. System suitability is the run-level check: resolution between the main peak and its nearest neighbour, peak symmetry, repeatability of replicate injections, and signal-to-noise at the reporting threshold. These parameters should be printed with the chromatogram, not asserted in a generic certificate.
Method validation is the higher-level evidence that the method measures what it claims. ICH Q2(R1) sets out the usual parameters: specificity, linearity, range, accuracy, precision, detection and quantitation limits. For peptide release testing, a fully validated method is not always required, but the method should at least be documented, transferred with the product, and demonstrated to separate the known impurities of that sequence. Ph. Eur. 2.2.46 provides the general framework for chromatographic separation techniques and the terms used to describe performance.
How to verify a purity claim without a full laboratory
You do not need an in-house mass spectrometer to sanity-check a supplier. Ask for the chromatogram for your lot, with the method. Look for a symmetrical main peak, an integration table that accounts for the minor peaks, and a run time long enough to elute hydrophobic impurities. Ask for the mass spectrum and check that the reported mass matches the sequence you ordered and that the error is stated in ppm.
For higher-confidence work, send a sealed vial to an independent laboratory and request HPLC purity, mass confirmation and water content. Compare the retention profile with the supplier chromatogram; the numbers need not match exactly, but the impurity pattern should be recognisably the same. MOL Changes provides chromatogram, spectrum and COA with every batch, and re-testing of retained samples is available through peptide testing. If you are selecting a supplier rather than auditing one batch, the supplier verification guide covers the rest of the evidence trail.
Frequently asked questions
Is HPLC purity the same as peptide content?
No. HPLC purity is a ratio of peak areas in a chromatogram. Peptide content is the mass fraction of peptide in the vial, after subtracting water, counter-ion, residual solvent and salts. A 97% pure batch can be 84% peptide, and dosing should be calculated from content.
What purity should I specify for a custom peptide?
For general research use, 95% by HPLC is a common specification. For receptor binding, analytical standards or in vivo work, 98%+ is preferable. Very long or hydrophobic sequences may not reach 98% economically, in which case the impurity profile matters more than the headline number.
How is peptide purity verified independently?
Send a sealed sample to an accredited or independent analytical laboratory and request reversed-phase HPLC purity with the method, mass confirmation, and water content. Compare the impurity pattern with the supplier chromatogram. Independent testing is the strongest check when the supplier cannot provide raw data.
What is a peptide assay and why does it matter?
An assay measures how much peptide is present, usually by amino acid analysis, nitrogen determination or quantitative HPLC against a standard. It matters because purity tells you the proportion of the target molecule in the UV-visible material, while assay tells you the amount you actually have.
Why does my peptide weigh less than expected?
Vial content is usually the total mass of powder, which includes counter-ion, water and residual solvent. If you need 10 mg of peptide, you may need 11.5 to 12 mg of powder at 84% content. Check the peptide content figure on the COA and calculate from that.
Does 98% purity mean 98% of the powder is peptide?
No. It means 98% of the integrated UV signal at the detection wavelength came from the main peak. Water and trifluoroacetate are invisible to the detector and can account for 10 to 20% of the mass. Only an assay combined with water and counter-ion data establishes peptide content.
Sources and scope
This answer is based on peer-reviewed peptide chemistry and analytical literature, pharmacopoeial requirements (USP <503>, Ph. Eur. 2.2.29 and 2.2.46), FDA and EMA guidance on peptide drug substances, and MOL Changes in-house synthesis and testing data. Product statements describe research-grade peptides supplied for laboratory and manufacturing use. They are not medical advice and are not a substitute for clinical judgement.
